- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02778126
A Study of Prexasertib (LY2606368) in Participants With Advanced Cancer
July 30, 2019 updated by: Eli Lilly and Company
Disposition of [¹⁴C]LY2606368 Following Intravenous Administration in Patients With Advanced and/or Metastatic Solid Tumours
The main purpose of this study is to evaluate the safety of the study drug known as Prexasertib (LY2606368) in participants with advanced cancer or cancer that has spread to other parts of the body.
This study will involve a single dose of ¹⁴C radiolabelled Prexasertib .
This means that a radioactive substance, carbon 14, will be incorporated into the study drug.
This will provide information about the study drug and its breakdown products and will help determine how much passes from the blood into urine, feces and expired air.
After a minimum 14-day washout period following the [¹⁴C] Prexasertib dose, participants will be allowed to receive continued access to Prexasertib as outpatients.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
6
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Liverpool, United Kingdom
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician.
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Have a histological or cytological diagnosis of cancer (solid tumour), with clinical or radiologic evidence of locally advanced and/or metastatic disease, for which no life-prolonging therapy exists
- Have the presence of measurable and/or nonmeasurable disease as defined by the Response Evaluation Criteria In Solid Tumours
- Have Body Surface Area (BSA) greater than or equal to (≥)1.62 meter squared (m²) and less than or equal to (≤) 1.90 m²
- Have adequate organ function
- Have a performance status of ≤2 on the Eastern Cooperative Oncology Group (ECOG) scale
- Have an estimated life expectancy, in the judgment of the investigator, that will permit the participant to complete 1 full cycle of treatment (beyond the initial [¹⁴C]prexasertib dose)
Exclusion Criteria:
- Have received treatment within 28 days of the initial dose of study drug with an investigational product or non-approved use of a drug or device
- Have serious pre-existing medical conditions (left to the discretion of the investigator)
- Have symptomatic central nervous system (CNS) malignancy or metastasis (screening not required)
- Have current haematologic malignancies or acute or chronic leukaemia
- Have an active fungal, bacterial, and/or known viral infection
- Have participated in a ¹⁴C (carbon) study within the last 6 months prior to screening for this study
- Have a second primary malignancy that in the judgment of the investigator and sponsor may affect the interpretation of results
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: [¹⁴C]Prexasertib
170 milligrams (mg) of prexasertib containing approximately 50 μCi [¹⁴C] prexasertib radiotracer administered intravenously (IV) as a 1 hour continuous IV infusion.
|
Administered IV Infusion
Other Names:
|
Experimental: Prexasertib
105 milligrams per square meter (mg/m²) of prexasertib administered IV as a 1 hour continuous IV infusion once every 14 days (14 day cycles). Treatment may continue until discontinuation criteria are met. Treatment for this arm was administered after ¹⁴C administration (¹⁴C was administered during first phase of the study) |
Administered IV Infusion
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Urinary Excretion of LY2606368 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered
Time Frame: Baseline through 120 hours after administration of study drug
|
Baseline through 120 hours after administration of study drug
|
Fecal Excretion of LY2606368 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered
Time Frame: Baseline through 120 hours after administration of study drug
|
Baseline through 120 hours after administration of study drug
|
LY2606368 Radioactivity in Expired Air Over Time Expressed as a Percentage of the Total Radioactive Dose Administered
Time Frame: Baseline through 120 hours after administration of study drug
|
Baseline through 120 hours after administration of study drug
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Pharmacokinetics: Maximum Concentration (Cmax) of LY2606368 and Radioactivity
Time Frame: Predose through 120 hours after administration of study drug
|
Predose through 120 hours after administration of study drug
|
Pharmacokinetics: Area Under the Concentration Time Curve from Time Zero to the Last Measured Concentration (AUC0-tlast) of LY2606368 and Radioactivity
Time Frame: Predose through 120 hours after administration of study drug
|
Predose through 120 hours after administration of study drug
|
Pharmacokinetics: Area Under the Concentration Time Curve from Time Zero to Infinity (AUC0-∞) of LY2606368 and Radioactivity
Time Frame: Predose through 120 hours after administration of study drug
|
Predose through 120 hours after administration of study drug
|
Relative Abundance of LY2606368 As Measured by Percentage of Radioactivity in Feces and Urine
Time Frame: Baseline through 120 hours after administration of study drug
|
Baseline through 120 hours after administration of study drug
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 22, 2016
Primary Completion (Actual)
April 29, 2017
Study Completion (Actual)
July 27, 2017
Study Registration Dates
First Submitted
May 18, 2016
First Submitted That Met QC Criteria
May 18, 2016
First Posted (Estimate)
May 19, 2016
Study Record Updates
Last Update Posted (Actual)
August 1, 2019
Last Update Submitted That Met QC Criteria
July 30, 2019
Last Verified
July 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 15556
- I4D-EW-JTJG (Other Identifier: Eli Lilly and Company)
- 2015-003126-13 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Cancer
-
STORM Therapeutics LTDRecruitingCancer | Advanced Solid Tumor | Advanced CancerUnited States
-
Merck Sharp & Dohme LLCCompletedAdvanced Cancer Relapsed | Advanced Cancer Refractory
-
Teon Therapeutics, Inc.Merck Sharp & Dohme LLCTerminatedCancer | Advanced Solid Tumor | Advanced Cancer | OncologyUnited States
-
BiOneCure Therapeutics Inc.RecruitingCancer | Advanced Solid Tumor | Advanced Cancer | OncologyUnited States
-
Zhejiang UniversityRecruitingAdvanced Colorectal Cancer | Advanced Hepatocellular Carcinoma | Advanced Gastric Cancer | Advanced Pancreatic CancerChina
-
PfizerTerminatedAdvanced Solid Tumors | Advanced CancerUnited States
-
Avera McKennan Hospital & University Health CenterCompleted
-
AVEO Pharmaceuticals, Inc.CompletedAdvanced Cancer | Refractory CancerUnited States
-
Vanderbilt-Ingram Cancer CenterNational Institutes of Health (NIH)Active, not recruitingAdvanced Cancer | Relapsed Cancer | Refractory CancerUnited States
-
University Health Network, TorontoUniversity of UlmRecruiting
Clinical Trials on [¹⁴C]Prexasertib
-
Dana-Farber Cancer InstituteEli Lilly and CompanyCompleted
-
Eli Lilly and CompanyCompletedOvarian CancerUnited States, Israel, Spain, Korea, Republic of, Australia, Belgium, United Kingdom, Italy
-
Eli Lilly and CompanyCompletedSmall Cell Lung CancerSpain, United States, Germany, Ukraine, France, Greece, Turkey, Netherlands, United Kingdom, Korea, Republic of
-
Eli Lilly and CompanyCompletedCarcinoma, Non-Small-Cell Lung | Advanced Cancer | Anal Squamous Cell Carcinoma | Squamous Cell Carcinoma | Carcinoma, Squamous Cell of Head and Neck | Lung Squamous Cell Carcinoma Stage IVUnited States
-
Dana-Farber Cancer InstituteCompletedAdvanced CancersUnited States
-
National Cancer Institute (NCI)TerminatedBreast Cancer | Ovarian Cancer | Prostate CancerUnited States
-
Eli Lilly and CompanyCompleted
-
Eli Lilly and CompanyCompletedColorectal Cancer | Metastatic Cancer | Non-small Cell Lung Cancer | Advanced CancerUnited States, Germany
-
Baylor Research InstituteEli Lilly and CompanyCompletedTriple Negative Breast CancerUnited States
-
Acrivon TherapeuticsGOG FoundationRecruitingPlatinum-resistant Ovarian Cancer | Urothelial Carcinoma | Endometrial AdenocarcinomaUnited States